- Home
- ADPT vs EVCM Comparison
ADPT vs EVCM Comparison
Compare ADPT & EVCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- EVCM
- Stock Information
- Founded
- ADPT 2009
- EVCM 2006
- Country
- ADPT United States
- EVCM United States
- Employees
- ADPT N/A
- EVCM N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- EVCM EDP Services
- Sector
- ADPT Health Care
- EVCM Technology
- Exchange
- ADPT Nasdaq
- EVCM Nasdaq
- Market Cap
- ADPT 1.8B
- EVCM 1.7B
- IPO Year
- ADPT 2019
- EVCM 2021
- Fundamental
- Price
- ADPT $12.92
- EVCM $10.54
- Analyst Decision
- ADPT Strong Buy
- EVCM Buy
- Analyst Count
- ADPT 8
- EVCM 9
- Target Price
- ADPT $12.38
- EVCM $11.89
- AVG Volume (30 Days)
- ADPT 2.1M
- EVCM 219.7K
- Earning Date
- ADPT 08-05-2025
- EVCM 08-06-2025
- Dividend Yield
- ADPT N/A
- EVCM N/A
- EPS Growth
- ADPT N/A
- EVCM N/A
- EPS
- ADPT N/A
- EVCM N/A
- Revenue
- ADPT $205,216,000.00
- EVCM $710,678,000.00
- Revenue This Year
- ADPT $24.39
- EVCM N/A
- Revenue Next Year
- ADPT $20.44
- EVCM $6.31
- P/E Ratio
- ADPT N/A
- EVCM N/A
- Revenue Growth
- ADPT 21.60
- EVCM 14.15
- 52 Week Low
- ADPT $3.98
- EVCM $8.10
- 52 Week High
- ADPT $13.37
- EVCM $12.34
- Technical
- Relative Strength Index (RSI)
- ADPT 69.79
- EVCM 47.59
- Support Level
- ADPT $10.66
- EVCM $10.30
- Resistance Level
- ADPT $13.37
- EVCM $10.95
- Average True Range (ATR)
- ADPT 0.81
- EVCM 0.51
- MACD
- ADPT 0.23
- EVCM -0.05
- Stochastic Oscillator
- ADPT 86.82
- EVCM 29.06
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About EVCM EverCommerce Inc.
EverCommerce Inc provides tailored Software-as-a-Service solutions for service-based small- and medium-sized businesses (SMBs) in-home services, health services, and fitness & wellness. With a platform serving approximately 708,000 customers across three core verticals, including numerous micro-verticals, their solutions address diverse needs within these sectors. Revenue is primarily generated from the United States. Operating in a single segment, their vertically-tailored SaaS offerings cater to SMBs' specialized demands, enabling them to automate processes, generate business, and enhance customer loyalty. The majority of customers contribute modest revenue, with a small percentage contributing higher amounts.